HUMAN IMMUNODEFICIENCY VIRUS-HEPATITIS C VIRUS COINFECTION: A REVIEW ON NECESSITY OF DIETARY COMPOUNDS FOR ANTIRETROVIRAL THERAPY
Human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection is a major health problem around worldwide. One-third of the HIV-infected patients suffer from chronic hepatitis (HCV). The risk factors of coinfected patients are very high while compared to the monoinfected patients; they are having higher HCV viral load is associated with a severe liver damage. The use of highly active antiretroviral therapy (HAART) dramatically increases the survival of HIV/HCV-coinfected patients by preventing the depletion of CD4 cell counts and delaying the progression of fibrosis which reduces the complications related to end-stage liver damage. Reverse-transcriptase inhibitors and protease inhibitors are very commonly used drugs for the treatment of coinfection. Combination drugs and synthetic drugs are playing a pivotal role in the coinfection therapy. Under HAART, the coinfected patients are affected by many adverse effects such as mitochondrial toxicity, hypersensitivity, and lipodystrophy syndrome. However, the adverse effects of most herbal drugs are relatively less frequent when the drugs are used properly compared with synthetic drugs; it may help to protect the patients from severe adverse effects. This review collates to the importance of plant-derived drugs for the treatment of HIV-HCV coinfection.
2. Kumarasamy N, Snigdha V, Timothy PF, Kenneth HM, Suniti S. Clinical profile of HIV in India. Indian J Med Res 2005;121:377-95.
3. Chen SL, Morgan TR. The Natural History of Hepatitis C Virus (HCV) Infection. Int J Med Sci 2006;3:47-52.
4. Chen YJ, Feeney RE, Chung TR. HCV and HIV co-infection: Mechanisms and management. Nat Rev Gastroenterol Hepatol 2014;11:362-71.
5. Chandra N, Joshi N, Raju YS, Kumar A, Teja DV. Hepatitis B and/or C co-infection in HIV infected patients: A study in a tertiary care centre from south India. Indian J Med Res 2013;138:950-4.
6. Kolgiri V, Patil VW, Nagar V. Correlation of total antioxidant status (TAS) with DNA damage in HIV/AIDS patients. Int J Pharm Pharm Sci 2016;8:240-4.
7. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. Can Med Assoc J 2004;170:229-38.
8. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
9. Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res 2000;33:179-89
10. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci 2012;16:1473 83.
11. Bessone F. HIV/HCV COINFECTION. Gaz mÃ©d Bahia 2009;79:24-7.
12. HIV/AIDS in India. Available from: https://www.en.wikipedia.org/ wiki/HIV/AIDS_in_India.
13. Thomas LD, Shih WJ, Alter JH, Vlahov D, Cohn S, Hoover RD, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996;174:690-5.
14. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996;23:1117-25.
15. Weber R, Sabin CA, Friis-MÃ¸ller N. Liver-related deaths in persons infected with the human immunodeficiency virus: The D: A: D study. Arch Intern Med 2006;166:1632-41.
16. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-7.
17. Rockstroh JK, Spenglerb U. HIV and Hepatitis C Virus Infection. Lancet 2004;4:437-44.
18. Cox J, Hamelin AM. Linden MT, Moodie EE, Anema A, Rollet- Kurhajec KC, et al. Food insecurity in HIV-Hepatitis C virus co-infected individuals in Canada: The importance of Co-morbidities. AIDS Behav 2017;21:792-802.
19. Weinstock DM, Merrick S, Malak SA, Jacobs J, Sepkowitz KA. Hepatitis C in an urban population infected with the human immunodeficiency virus. AIDS 1999;13:2593-5.
20. Weissenbacher M, Rossi D, Radulich G, Sosa-EstÃ¡ni S, Vila M, Vivas E, et al. High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina. Clin Infect Dis 2003;37:S348-52.
21. Shepard WC, Finelli L, Alter JM. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
22. ICMR Ministry of Health and Family Welfare Government of India. India HIV Estimations 2015 Technical Report. New Delhi: National AIDS Control Organisation and National Institute of Medical Statistics, ICMR Ministry of Health and Family Welfare Government of India.
23. Kumarasamy N, Solomon S, Flanigan TP, Hemalatha R, Thyagarajan SP, Mayer KH. Natural History of human immunodeficiency virus disease in south India. Clin Inf Dis 2003;36:79-85.
24. Sud A, Sigh J, Dhiman RK, Wanchu A, Singh S, Chawla Y. Hepatitis b virus coinfection in HIV infected patients. Trop Gastroenterol 2001;22:90-2.
25. Saha MK, Chakrabarti S, Panda S, Naik TN, Manna B, Chatterjee A, et al. Prevalence of HCV and HBV infection amongst HIV seropositive intravenous drug users and their non-injecting wives in Manipur, India. Indian J Med Res 2000;111:37-9.
26. Marx MA, Murugavel KG, Sivaram S, Balakrishnan P, Steinhoff M, Anand S, et al. The association of health care use and hepatitis C virus information in a random sample of urban slum community residents in southern India. Am J Trop Med Hyg 2003;68:258-62.
27. Battacharya S, Badrinath S, Hamide A, Sujatha S. Coinfection with hepatitis C virus and human immunodeficiency virus among patients with sexually transmitted diseases in Pondicherry, South India. Indian J Pathol Microbiol 2003;46:495-7.
28. World Health Organization. WHO Library Cataloguing-in-Publication Data Global health risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva: World Health Organization; 2009. Available from: http://www.who.int/healthinfo/global_burden_disease/ GlobalHealthRisks_report_full.pdf.
29. HIV/AIDS in India. Available from: http://www.en.wikipedia.org/wiki/ HIV/AIDS_in_India.
30. Saravanan S, Velu V, Kumarasamy N, Nandakumar S, Murugavel KG, Balakrishnan P, et al. Coinfection of hepatitis B and hepatitis C virus in HIV-infected patients in south India. World J Gastroenterol 2007;13:5015-20.
31. Mukhopadhya A. Hepatitis C in India. J Biosci 2008;33:465-73.
32. Devi KH, Brajachand N, Singh HL, Singh YM. Coinfectionby human immune deficiency virus, hepatitis B andhepatitis C virus in injecting drug users. J Commun Dis 2005;37:73-7.
33. Sahelian R. HIV AIDS supplement vitamin herb information - Natural therapy and treatment. News letter, November 2, 2017. Available from: http://www.raysahelian.com/hiv.html
34. Poordad F, Reddy R, Martin P. Rapid virologic response: A new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46:78-84.
35. Sharma R, Duggal N, Malhotra S, Shrivastava D, Hans C. Antifungal susceptibility of Cryptococcus neoformans isolates from fungal meningitis in AIDS patients in India. Int J Pharm Pharm Sci 2014;6:584 6.
36. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: Efficacy, side effects, and complications. Gut 2006;55:1350-9.
37. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
38. Duggan J, Peterson WS, Schutz M, Khuder S, Charkraborty J. Use of complementary and alternative therapies in HIV-infected patients. AIDS Patient Care STDs 2004;15:159-67.
39. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998;338:1345-51.
40. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
41. Fried MW, Shiffman MI, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
42. Soriano V , Nunez M, Miralles C, Berdun MA, Aguirrebengoa K, Ocampo A, et al.The PRESCO trial: Role of Extended Duration of Therapy with Pegylated Interferon Plus Weight Based Ribavirin Doses in 389 HIV-HCV Coinfected Patients. In: International Congress on Drug Therapy in HIV Infection (Glasgow, UK); 2006.
43. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection: Epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci 2012;16:1473 83.
44. North CP, Hawkins LK, Rossiter TS, Hawley NM, Bhattacharya R, Landis CS. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun 2017;1:248 55.
45. HCV Guidance: Recommendations for Testing, Managing, Treating Hepatitis C. Infectious Disease Society of America. Initial Treatment of HCV Infection; 2017.Available from: http://www.hcvguidelines.org/ full-report/initial-treatment-hcv-infection.
46. Kumarasamy N, Lai A, Cecelia AJ, Sagayam S, Solomon S, Flanigan TP, et al. Toxicities and Adverse Events Following Generic HAART in South Indian HIV-infected Individuals. 7th International Congress on Drug Therapy and HIV infection, Glasgow, UK, Nov 14- 18, 2004. Abstract no.P189
47. Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-5.
48. Lo Re K 3rd, Kostman J, Amorosa V. Management complexities HIV/ Hepatitis C virus coinfection in the twenty-first century. Clin Liver Dis 2008;12:587-609.
49. Kumar AP, Parthasarathi G, Sudheer AP, Mothi SN, Swamy VH, Rao S. Incidence and risk factors of renal impairment in hiv-1 infected patients receiving tenofovir based antiretroviral therapy in a south indian hospital. Int J Pharm Pharm Sci 2017;9:152-5.
50. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; 2009. Available from: http://www.aidsinfo.nih.gov/guidelines.
51. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo humpâ€ in men with HIV-1 infection. Lancet 1998;351:867-70.
52. Cinque P, Koralnik JI, Gerevini S, Miro MJ, Price WR. Progressive multifocal leukoencephalopathy complicating HIV-1 infection. Lancet Infect Dis 2009;9:625-36.
53. Side Effects of HIV and AIDS Drugs.Available from: http://www. webmd.com/hiv-aids/aids-hiv-medication-side-effects.
54. Montessori V, Press N, Harris M, Akagi L, Julio SG. Montaner Adverse effects of antiretroviral therapy for HIV infection. J Appl Math Comput 2004;170:229-38.
55. Thyagarajan SP, Jayaram S, Gopalakrishnan V, Hari R, Jeyakumar P, Sripathi MS. Herbal medicines for liver diseases in India. J Gastroenterol Hepatol 2002;17:S370-6.
56. GonÃ§alves D, Lima C, Ferreira P, Costa P, Costa A, Figueiredo W, et al. Orange juice as dietary source of antioxidants for patients with hepatitis C under antiviral therapy. Food Nutr Res 2017;61:1296675.
57. Calland N, Dubuisson J, Rouille Y, Seron K. Hepatitis C virus and natural compounds: A new antiviral approach? Viruses 2012;4:2197 217.
58. Human Metabolome Database (HMDB). Available from: https:// pubchem.ncbi.nlm.nih.gov/source/Human%20Metabolome%20 Database%20(HMDB).
59. Monforte AD, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen. AIDS 2000;14:499 507.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.